Literature DB >> 28559493

Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB-MI Paradox.

Martin H Strauss1, Alistair S Hall2.   

Abstract

Entities:  

Keywords:  angiotensin II receptor blocker; angiotensin converting enzyme inhibitor; cardiovascular mortality; hypertension; meta-analysis; myocardial infarction

Mesh：

Substances：

Year:  2017        PMID： 28559493     DOI： 10.1161/CIRCULATIONAHA.117.026112

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  12 in total

Review 1.  Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.

Authors:  Simon B Dimmitt; Hans G Stampfer; Jennifer H Martin; Robin E Ferner
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

Review 2.  Translating the dose response into risk and benefit.

Authors:  John B Warren
Journal:  Br J Clin Pharmacol       Date:  2019-05-17       Impact factor: 4.335

3.  Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies.

Authors:  Csaba András Dézsi; Maria Glezer; Yuri Karpov; Romualda Brzozowska-Villatte; Csaba Farsang
Journal:  Adv Ther       Date:  2020-11-05       Impact factor: 3.845

4.  Comparative effectiveness of ACE inhibitors and angiotensin receptor blockers in patients with prior myocardial infarction.

Authors:  Dennis Ko; Paymon Azizi; Maria Koh; Alice Chong; Peter Austin; Therese Stukel; Cynthia Jackevicius
Journal:  Open Heart       Date:  2019-05-04

5.  Assessing the risk of angiotensin receptor blockers on major cardiovascular events: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Yara Wanas; Rim Bashir; Nazmul Islam; Luis Furuya-Kanamori
Journal:  BMC Cardiovasc Disord       Date:  2020-04-21       Impact factor: 2.298

Review 6.  A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril.

Authors:  Arnaud Ancion; Julien Tridetti; Mai-Linh Nguyen Trung; Cécile Oury; Patrizio Lancellotti
Journal:  Cardiol Ther       Date:  2019-10-01

7.  Comparative Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Coronary Artery Bypass Grafting.

Authors:  Jeayoun Kim; Jungchan Park; Jong-Hwan Lee; Jeong Jin Min; Seung-Hwa Lee; Young Tak Lee; Wook Sung Kim; Sanghoon Song; Jung Hyun Yeo; Hyojin Cho
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

Review 8.  Should Angiotensin-Converting Enzyme Inhibitors ever Be Used for the Management of Hypertension?

Authors:  Jeffrey M Turner; Ravi Kodali
Journal:  Curr Cardiol Rep       Date:  2020-07-09       Impact factor: 2.931

9.  Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis.

Authors:  Jonathan A Batty; Mengyao Tang; Marlous Hall; Roberto Ferrari; Martin H Strauss; Alistair S Hall
Journal:  Syst Rev       Date:  2018-08-25

10.  Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and long-term follow-up outcome.

Authors:  Yue Zhang; Xiaosong Ding; Bing Hua; Qingbo Liu; Hui Chen; Xue-Qiao Zhao; Weiping Li; Hongwei Li
Journal:  J Transl Med       Date:  2020-04-01       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.